Ken Griffin Arbutus Biopharma Corp Put Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Put Options
8 transactions
Others Institutions Holding ABUS
# of Institutions
150Shares Held
97.5MCall Options Held
3.49MPut Options Held
421K-
Morgan Stanley New York, NY21MShares$76.3 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$46.8 Million30.08% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$42 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$32.5 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.57MShares$31.2 Million10.59% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $546M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...